Retrospective clinical studies suggest that ABC-DLBCL patients with MCD genetic subtype (MYD88 and CD79B mutation) showed higher expression of IRF4 and MYC signature, and strong sensitivity to BTK inhibitor with R-CHOP [77,78]. This evidence concerns the gene MYC and aneurysmal bone cyst.